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Abstract
MicroRNAs (miRNAs) have been shown to be involved in different aspects of cancer biology including tumor angiogenesis.
In this study, we identified that two miRNAs, miR-199a and miR-125b were downregulated in ovarian cancer tissues and cell
lines. Overexpression of miR-199a and miR-125b inhibited tumor-induced angiogenesis associated with the decrease of HIF-
1a and VEGF expression in ovarian cancer cells. Moreover, the levels of miR-199a and miR-125b were negatively correlated
with VEGF mRNA levels in ovarian tissues. We further showed that direct targets of miR-199a and miR-125b HER2 and HER3
were functionally relevant. Forced expression of HER2 and HER3 rescued miR-199a- and miR-125b-inhibiting angiogenesis
responses and Akt/p70S6K1/HIF-1a pathway. This study provides a rationale for new therapeutic approach to suppress
tumor angiogenesis using miR-199a, miR-125b, or their mimics for ovarian cancer treatment in the future.
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Introduction
Ovarian cancer is the fifth leading cause of cancer death in
women and the most lethal gynecologic malignancy in the
Western world [1]. In the U.S., the overall lifetime risk of
developing ovarian cancer is estimated to range between 1 in 56
(1.8%) and 1 in 71 (1.4%) women [2]. Despite recent advances in
chemotherapeutic treatments that have improved the initial
responses, the 5-year survival rate for women with advanced-
stage ovarian cancer is only about 30% after initial diagnosis [3].
Consequently, a better understanding of the mechanisms leading
to the initiation and progression of ovarian cancer is required to
develop new targets and therapeutic strategies.
Angiogenesis is required for the cancer development and
growth. Without angiogenesis, cancer cells inside the tumor will
undergo apoptosis [4]. The angiogenesis switch depends on the
balance of angiogenesis activators and inhibitors. Recent studies
have shown that some miRNAs are involved in the regulation of
vascular development and angiogenesis [5]. The global inhibition
of Dicer and Drosha, two key enzymes for miRNAs biogenesis led
to impaired angiogenesis [6]. Some miRNAs such as miR-10b and
miR-196b have been identified to promote angiogenesis by
directly regulating bone marrow-derived endothelial progenitor
cells (EPCs) [7], whereas miR-126 induces angiogenesis by
increasing vascular endothelial cell growth factor (VEGF) expres-
sion [8]. Conversely, miR-221 and miR-222 inhibit angiogenesis
by targeting human proto-oncogene c-Kit receptors in endothelial
cells [9]. Data from miRNA microarray analysis shows that some
miRNAs are aberrantly expressed in ovarian cancer [10], indicating
the involvement of miRNAs in ovarian cancer development.
However, the roles of miRNAs in regulating angiogenesis in
ovarian cancer remain to be determined. Our preliminary data
indicated that miR-199a and miR-125b may be involved in
angiogenesis. In this study, we plan to investigate: 1) the expression
levels of miR-199a and miR-125b in human ovarian tissues and
their correlation with potent angiogenesis inducer VEGF; 2) the
direct roles of miR-199a and miR-125b in affecting angiogenesis; 3)
what signaling molecules and pathway(s) are involved in miR-199a-
and miR-125b-inhibiting angiogenesis; and 4) which direct targets
of miR-199a and miR-125b are involved in angiogenesis, and miR-
199a- and miR-125b-regulated pathway(s).
Materials and Methods
Ethics Statement
The study protocol was approved by the Nanjing Maternal and
Child Care Service Center Institutional Review Board and the
informed written consents were given by all the patients. No
information related to the Health Insurance Portability and
Accountability Act was included in the study, which qualifies for
the status of NIH Exemption # 4.
Ovarian Cancer Tumor Tissues
The tissue samples of primary epithelial ovarian cancer and
normal ovarian tissues were collected by Nanjing Maternal and
Child Care Service Center, Nanjing, China. These tissues were
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partly snap-frozen in liquid nitrogen and stored at -80uC before
the analysis, and partly fixed for pathology diagnosis. In this study,
we used 33 ovarian papillary serous cystadenocarcinoma and 7
normal ovarian tissues.
Antibodies
Antibodies against p-AKT, total AKT, and p-p70S6K1 were
from Cell Signaling Technology (Beverly, MA); against p70S6K1
were from Santa Cruz Biotechnology (Santa Cruz, CA); against
total HER2 and HER3 were from Upstate Biotechnology
(Upstate, NY); and against HIF-1a and HIF-1b were from BD
Bioscience (Franklin Lakes, NJ).
Cell Culture and Generation of Stable Cell Lines
The human ovarian cancer cells OVCAR3 and A2780 were
purchased from ATCC (Manassas, VA, US). The immortalized
ovarian epithelial cells IOSE386 and IOSE397 were generated by
transfecting normal ovarian surface epithelial cells with the
immortalizing simian virus 40 early genes [11]. These cells were
cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS). The human
umbilical vein endothelial cells (HUVEC) (ATCC, Manassas, US)
were cultured in EBM-2 complete medium. Stable cell lines of
A2780 cells overexpressing HER2 were generated by transfecting
the pBaBe vector expressing HER2 cDNA without 39 UTR region
into 293 FT (Life technologies, Grand Island, NY, US) cells to
obtain infectious virus using FuGENE6 (Roche, Indianapolis, IN ).
A2780 cells were infected by the virus alone or carrying HER2 for
48 h, followed by selection in medium containing 1.0 mg/ml
puromycin for 7 days. Stable cell lines of OVCAR-3 cells
overexpressing HER3 was generated by transfecting the pRe-
ceiver-Lv105 vector expressing HER3 cDNA without 39 UTR
region into 293 FT cell using Trans-lentiviral package kit (Open
Biosystem, Huntsville, AL). OVCAR-3 cells were infected by
lentivirus carrying HER3, followed by the selection with puromycin
to obtain the stable cell lines. The similar method was used to
generate A2780 stable cell lines expressing HIF-1a cDNA. Human
HER2 cDNA clone with 39 UTR region was purchased from
Origene (Rockville, MD, US) for transient transfection.
miRNA Transfection
The negative control miRNA precursor, miR-199a and miR-125b
precursors were obtained from Applied Biosystem (Austin, TX). Cells
were cultured in 6-well plate to reach 60% confluency, and
transfected using miRNA precursors at 30 nM using X-treme Gene
siRNA transfection reagent (Roche,Mannheim,Germany) according
to the manufacturer’s instruction. Total proteins and RNAs were
prepared from the cells for analysis 60–70 h after the transfection.
Plasmid Constructs
The 39UTR-luciferase reporter constructs containing the 39UTR
regions of HIF-1a with wild-type and mutant binding sites of miR-
199a were amplified using PCR method. Total cDNAs was
obtained from A2780 cells. The PCR products were cloned into
the pMiR-luc reporter vector (Ambion) between Sac I and Hind III
sites, immediately downstream of the luciferase gene. The mutant
39UTR constructs were made by introducing four mismatch
mutations into the putative seed regions of HIF-1a. All the
constructs containing 39UTR inserts were sequenced and verified.
RT-PCR and Taqman qRT-PCR
Total RNAs were extracted using Trizol (Life technologies,
Carlsbad, CA). The cDNA synthesis was performed using
oligo(dT)18 primers and M-MLV reverse transcriptase. For VEGF
mRNA analysis, the primers used for PCR were as follows: VEGF
forward primer, 59-TCGGGCCTCCGAAACCATGA-39; VEGF
reverse primer, 59-CCTGGTGAGAGATCTGGTTC-39;
GAPDH forward primer, 59-CCACCCATGGCAAATTC-
CATGGCA-39; and GAPDH reverse primer, 59-TCTAGACGG-
CAGGTCAGGTCCACC-39. The PCR amplification was per-
formed at: 95uC for 5 min, followed by 28 cycles of 95uC for
1 min, 59uC for 45 s, 72uC for 1 min. Stem-loop RT-PCR was
used to determine miRNA expression levels in cells and tumor
tissues. The PCR primer pairs for miR-125b, miR-199a and U6
were synthesized by Shanghai Sangon Biological Engineering
Technology and Services (Shanghai, China). The primers for miR-
125b, miR-199a and U6 were as follows: miR-125b were 59-
GCAACCTTGCGACTATAACCATCACAAGTTA-39 (stem-








CACAT-39 (antisense). The expression levels of miR-125b, miR-
199a in samples were measured in terms of threshold cycle value
and normalized to U6 levels as an internal control. All reactions
were performed in triplicates.
For Taqman RT-PCR, small RNAs were extracted from
cultured cells using the mirVana miRNA isolation kit (Ambion,
Austin, TX). Two-step Taqman real-time PCR analysis was
performed to assess miRNA levels using Taqman miRNA reverse
transcription kit and Taqman universal PCR master mix (Applied
Biosystem, Austin, TX, USA) in accordance with manufacturer’s
instructions. Normalization was performed with U6 RNA. Each
analysis was performed in three replicates and three technical
replicates within each experiment.
Real-time RT-PCR for VEGF
Total RNAs in tissues were extracted using Trizol. Reverse
transcription reactions were performed by using High Capacity
RNA-to cDNA according to the manufacturer’s instructions. The
100 ng of RT product was used for PCR reaction using Power
SYBR Green PCR Master Mix Kit (Applied Biosystems,
Carlsbad, CA, USA). The primers of VEGF are: forward primer,
59-CGAGGGCCTGGAGTGTG-39; reverse primer, 59-CCGCA-
TAATCT GCATGGTGAT-39. The primers of GAPDH are:
forward primer, 59-ATGGGTGTGAACCATGA GAAGTATG-
39; reverse primer: 59GGTGCAGGAGGCATTGCT-39.
Luciferase Reporter Assay
Cells were seeded on 12-well plates and cultured to 50–60%
confluency. The cells were transiently transfected with HIF-1a
39UTR miRNA luciferase (luc) reporters or VEGF luc reporter
(0.4 mg), b-gal plasmid (0.2 mg), pre-miRNA precursor (0.4 mg)
using lipofectamine according to the manufacturer’s instruction.
The cells were harvested and lysed with reporter lysis buffer
(Promega, Madison, WI) 48 h after the transfection. The luc
activities in the cellular extracts were determined using the luc
assay system (Promega). The b-gal activity was measured with
assay buffer (200 mM phosphate, 2 mM MgCl2, 100 mM b-
mercaptoethanol, 1.33 mg/ml o-nitrophenyl b-D-galactopyrano-
side). The relative luc activity was calculated by the ratio of luc/b-
gal activity, and normalized to that of the control cells.
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Western Blotting
The cells were harvested and washed in cold 16 PBS buffer,
and lysed in ice-cold RIPA buffer supplemented with protease
inhibitors on ice for 30 min. Cell debris was discarded by
centrifugation at 12,000 rpm for 10 min at 4uC. The protein
concentrations were assayed using Bio-Rad protein assay reagents.
Protein samples were subjected to immunoblotting analysis.
Tube Formation Assay
Human umbilical vein endothelial cells (HUVEC) were cultured
in EBM-2 complete medium, and switched to EBM-2 basal
Figure 1. MiR-199a and miR-125b are down-regulated in ovarian cancer tissues and cells. (A) The expression levels of miR-199a and miR-
125b in human epithelial ovarian carcinoma tissues and normal ovarian tissues determined by RT-PCR. Total of 33 ovarian epithelial cancer tissues
and 7 normal ovary tissues were analyzed. Representative samples (n = 6 for each group) are shown. The expression level of U6 was used as loading
control. (B) Taqman RT-PCR was performed to assess miR-125b and miR-199a expression levels using 33 ovarian cancer tissues and 7 normal tissues.
The bar refers to the mean for each group. The values were normalized to the mean of cancer tissues. *Significantly different compared with that of
control (P,0.05). (C) The miR-199a and miR-125b expression levels were analyzed using Taqman qRT-PCR in ovarian cancer cell lines. Relative
expression levels were represented as RQ using of 22DDCT methods. Each data sample was normalized to the U6 expression level and that in OVCAR-3
cells. Mean 6 SE values were from three separate experiments. #Significantly different compared with OVCAR-3 (P,0.05). *Significantly different
compared with A2780 (P,0.05).
doi:10.1371/journal.pone.0056647.g001
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medium containing 0.2% FBS for 24 hours to be used for the tube
formation assay. The conditioned media were prepared from
different ovarian cancer cells by replacing normal culture medium
with serum-reduced medium (1% FBS). After culture for 24 h, the
serum-reduced medium was collected and stored at 220uC for later
use. The HUVEC cells were trypsinized, counted and resuspended in
EBM-2 basic medium. Then the cells were mixed with equal volume
of the conditioned medium and seeded on Matrigel-pretreated 96-
well plate at density of 26104 cells/well. Tube formation was
observed under light microscope after 12 h, and photographed. The
total length of the tubes for each well was measured using CellSens
Standard software. Each treatment has six replicates.
CAM Assay
White Leghorn fertilized chicken eggs were incubated at 37uC
under constant humidity. Different ovarian cancer cells and
control cells were transfected with certain miRNA precursors or
treated as specifically indicated. These cells were trypsinized,
counted and resuspended in the serum-free medium. The cell
suspensions were mixed with Matrigel at 1:1 ratio and implanted
onto the chorioallantoic membranes (CAM) of chicken eggs at Day
9. Tumor angiogenesis responses were analyzed 5 days after the
implantation. The tumor/Matrigel plugs were trimmed off CAM
and photographed. The number of blood vessels as the index of
angiogenesis was obtained by counting the branches of blood
vessels in three representative areas (1.5 mm2) by two observers in
a double blind manner.
Statistic Analysis
All the results were obtained from at least three independent
experiments. Most results were presented as mean 6 SE from
independent experiments, and analyzed by Student’s t test, One-
way ANOVA, and/or Pearson correlation analysis. All results
were analyzed by SPSS for Windows, version 11.5. Differences
were considered significant at a value of P#0.05.
Results
MiR-199a and miR-125b are Down-regulated in Ovarian
Cancer Tissues
According to miRNA array analysis, miR-199a and miR-125b
were down-regulated in human epithelial ovarian carcinoma
tissues compared to normal ovarian tissues [10,12]. We used both
regular RT-PCR and Taqman qRT-PCR to examine miR-199a
and miR-125b expression levels in 33 human ovarian serous
adenocarcinomas tissues and 7 normal human ovarian tissues, and
found that miR-199a and miR-125b expression levels were
significantly lower in ovarian cancer tissues than those in normal
tissues (Figures 1A, B). Similarly miR-199a and miR-125b
expression levels in ovarian cancer cell lines OVCAR-3, A2780
were much lower than those in immortalized ovarian epithelial cell
line IOSE397 (Figure 1C).
MiR-199a and miR-125b Suppress Tumor Angiogenesis
via HIF-1a/VEGF Pathway
Angiogenesis is the essential process for tumor development [4].
We evaluated the potential roles of miR-199a and miR-125b in
angiogenesis. First, we performed tube formation assay using
human umbilical vein endothelial cells (HUVEC). No tube
formation by HUVEC cells was observed using EBM-2 basic
medium, whereas tube formation was strongly induced using
conditioned medium prepared from ovarian cancer cells OVCAR-
3 or A2780. The conditioned medium from OVCAR-3 and
A2780 cells overexpressing miR-199a or miR-125b induced
significantly less tube formation than that from the cells expressing
negative control miRNA (Figure 2A). Next, we employed chicken
chorioallantoic membrane (CAM) assay for studying angiogenesis
in vivo. MiR-199a and miR-125b overexpression in ovarian cancer
cells decreased their ability of inducing angiogenesis by 40% and
50%, respectively (Figure 2B). VEGF is the major angiogenesis
inducer both in physiological and pathological processes, while
HIF-1a is the major regulator of VEGF transcriptional activation
through the binding to the hypoxia response element of VEGF
promoter [13]. To examine whether HIF-1a/VEGF pathway is
involved in this process, the expression levels of HIF-1a protein
and VEGF mRNA were determined. As expected, miR-199a and
miR-125b remarkably inhibited HIF-1a and VEGF expression in
both cell lines (Figure 2C). This result suggests that miR-199a and
miR-125b repress angiogenesis potential of cancer cells through
inhibiting HIF-1a/VEGF expression. To test whether these
findings have potential clinical application, we measured VEGF
mRNA levels in ovarian cancer tissues by real time RT-PCR and
performed the correlation analysis of VEGF levels and relative
expression levels of miR-199a or miR-125b in these tissue samples.
An inverse correlation was observed between VEGF levels, and
miR-199a or miR-125b expression (P#0.05) (Fig. 2D), suggesting
that the expression of miR-199a or miR-125b regulates VEGF in
human cancer tissues. It has been reported that HIF-1a is the
direct target of miR-199a in cardiac myocytes [14], and this
prompted us to construct HIF-1a 39UTR reporter for validation.
However, we were unable to confirm the direct interaction
between miR-199a and HIF-1a in ovarian cancer cells (Figure S1),
suggesting an indirect effect of miR-199a on HIF-1a expression.
HER2 and HER3 Proteins are Highly Expressed in Ovarian
Cancer
Recent findings from our group and other group show that
HER2 is a direct target of miR-199a and HER3 is a direct target
of both miR-199a and miR-125b in A2780 and OVCAR-3 cells
[15,16]. Given the important roles of HER2 and HER3, there are
great interests in investigating HER2 and HER3 status in human
cancers; however, there is notable variability across the studies. In
this study we analyzed 33 human ovarian serous adenocarcinomas
and 7 normal ovarian tissues. Overall, 21 out of 33 cancer samples
and all 7 normal ovarian samples are HER2 positive whereas 29
out of 33 cancer samples and 6 out of 7 normal samples are HER3
positive. Scanning densitometry reveals that the average expres-
sion of HER2 in 21 HER2 positive ovarian cancer tissues was
higher relative to 7 HER2 positive normal ovarian tissues
(Figure 3A, B). The same trend was observed for HER3
expressions. To test HER2 and HER3 expression levels in ovarian
cancer cells, we found that SKOV3, OVCAR-3 and A2780 cells
have much higher expression levels than immortalized ovarian
epithelial cell lines IOSE 386 and IOSE 397 (Figure 3C). Taken
together, these results show that HER2 and HER3 proteins are
generally increased in ovarian cancer tissues and cancer cell lines.
MiR-199a and miR-125b Inhibit Angiogenesis via HER2
and HER3
To determine whether miR-199a and miR-125b decrease
angiogenesis potential by targeting HER2 and HER3, we
established ovarian cancer stable cell lines overexpressing HER2
and HER3 using HER2 and HER3 cDNA plasmids without 39
UTR regions, respectively. The HER2 and HER3 protein
expression was confirmed in these stable cell lines by immuno-
blotting (Figure 4A). Tube formation assay was initially conducted
MiR-199a and miR-125b Inhibit Tumor Angiogenesis
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to evaluate angiogenesis effects (Figures 4B, C). No tube formation
was observed by HUVEC cells cultured in basic medium, while
tube formation was induced by HUVEC cells cultured in
conditioned medium prepared from A2780 or OVCAR-3 cells.
The ectopic expression of miR-199a or miR-125b in OVCAR-3
and A2780 cells significantly impaired the tube formation. The
forced expression of HER2 and HER3 in the cells completely
restored the tube formation abilities even in the cells transfected
with miR-199a or miR-125b precursor, indicating that lack of
HER2 and HER3 39UTR regions makes cells resistant to the
miRNAs regulation. To further examine the roles of HER2 and
HER3 in tumor-induced angiogenesis, we analyzed tumor
angiogenesis responses in vivo by CAM model. The results were
entirely consistent with the data from the tube formation assay.
Tumor-induced angiogenesis was impaired by ectopic expression
of miR-199a or miR-125b and was reversed by HER2 or HER3
overexpression (Figures 4D, E). To further confirm the negative
regulation of miR-199a/125b on HER2 and/or HER3, OVCAR-
3 cells were transiently transfected with HER cDNA containing
miR-199a binding sites and miR-cont or miR-199a precursor to
get conditioned medium. Tube formation assay was performed to
assess the angiogenic potential of cancer cells. The results showed
that miR-199a was able to decrease the tube formation (Figure.
S2). Collectively, these results suggest that miR-199a and miR-
125b inhibit angiogenesis by directly targeting and inhibiting
HER2 and HER3 expression.
Overexpression of HER2 or HER3 in Ovarian Cancer Cells
Reversed the miRNA Effects via Akt/p70S6K1/HIF-1a/
VEGF Pathway
AKT and ERK1/2 are known downstream mediators of HER2
and HER3 [17]. The aberrant activation of AKT or ERK is
considered to be hallmarks of cancer [18]. To study whether miR-
199a and miR-125b utilize these two pathways, ovarian cancer
Figure 2. MiR-199a and miR-125b suppress tumor angiogenesis associated with reduction of HIF-1a and VEGF expression. (A)
HUVEC cells were cultured in serum free medium overnight and re-suspended in basic EBM-2 medium. To perform the tube formation assay, HUVEC
cells were incubated in basic EBM-2 medium; conditioned medium prepared from OVCAR-3 or A2780 transfected with pre-miR-control, pre-miR-125b
and pre-miR-199a, respectively. Tube formation was determined under light microscope in 12 h. Total tube length (mm) was presented as mean6 SE
from six replicates for each treatment. **Significantly different compared with OVCAR-3 control (P,0.01). ##Significantly different compared with
A2780 control (P,0.01). (B) A2780 cells were transfected with 30 nM pre-miR-125b, pre-miR-199a and pre-miR-control precursor, respectively. After
transfection (24 h), 26106 cells were trypsinized, suspended, and mixed with equal volume of Matrigel, and implanted onto the chicken CAMs of 10-
day-old chicken embryos. The branches of blood vessels were counted as the index of angiogenesis was obtained from the CAMs of 8–10 embryos
per treatment 96 h after implantation. The data represent as mean 6 SE of blood vessel numbers, which were normalized to that of the control.
**Significantly different compared with that of the control (P,0.05). (C) A2780 cells and OVCAR-3 cells were cultured under normoxic condition, and
transiently transfected as above to analyze HIF-1a and b-actin protein expression by immunoblotting and VEGF mRNA levels (VEGF-165 and VEGF-
121 isoforms) by RT-PCR. Quantification was performed by scanning densitometry. The results are obtained from triplicate experiments and
presented as mean 6 SE. *Significantly difference compared with the same cell lines transfected with miR-cont. (D) VEGF mRNA levels in human
ovarian cancer tissues (n = 33) were analyzed by SYBR Green qRT-PCR. The Pearson correlations were analyzed between miR-125b or miR-199a
expression and its corresponding VEGF expression in cancer tissues.
doi:10.1371/journal.pone.0056647.g002
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cells expressing vector alone, HER2, or HER3 were transfected
with miR-199a and miR-125b precursor; and analyzed for AKT
and ERK expression levels. Overexpression of miR-199a and
miR-125b resulted in decreased p-AKT levels, but not p-MAPK
level (Figure 5A). Forced expression of HER2 or HER3 alone was
sufficient to restore p-AKT expression levels in the cells with miR-
199a and miR-125b overexpression. P70S6K1 is a downstream
target of AKT and mTOR [19]. P70S6K1 may regulate HIF-1a
expression and tumor angiogenesis [20]. Overexpression of HER2
in breast cancer cells increased VEGF protein synthesis via
p70S6K1, resulting in enhanced angiogenesis [21]. In this study,
we found that miR-199a or miR-125b inhibited phosphorylation
of p70S6K1 and downstream HIF-1a and VEGF expression,
while enforced expression of HER2 or HER3 reversed such
inhibitory effects (Figures 5B, C). No significant difference was
observed in HER2 or HER3 overexpressing cells when transfected
with miR-199a or miR-125b. Similar results were obtained from
VEGF luciferase reporter activity assay (Figure 5D).
HIF-1 is known to regulate VEGF expression at the transcrip-
tional activation level [13]. We also examined the role of HIF-1a in
miR-199a- and miR-125b-inhibited angiogenesis by establishing an
A2780 cell stably overexpressing HIF-1a (Figure 5E). As we
expected, VEGF expression was attenuated by miR-199a and miR-
125b overexpression, and rescued by HIF-1a forced expression
(Figure 5F). CAM assay was performed and showed that miR-199a
or miR-125b alone was sufficient to inhibit A2780 cell-induced
angiogenesis, whereas HIF-1a overexpression restored miR-199a-
and miR-125b-inhibited angiogenesis (Figure 5G), suggesting that
inhibitory effects of miR-199a- and miR-125b on tumor-induced
angiogenesis are mediated by HIF-1a downregulation.
Discussion
A number of recent studies have identified altered miRNA
signatures in ovarian tumors. It has been reported that miR-200a,
miR-141, miR-200c and miR-200b were up-regulated whereas
Figure 3. HER2 and HER3 protein expression levels in ovarian cancer tissues. (A) The protein levels of HER2 and HER3 were evaluated in
human ovarian cancer tissues and normal ovarian tissues by immunoblotting (6 representatives HER2 or HER3 positive samples are shown for both
groups). The level of b-actin was used as loading control. (B) Scanning densitometry was used to quantify the relative expression levels of HER2 or
HER3. The scattered graphs showed HER2 or HER3 expression levels in HER2 or HER3 positive samples in normal tissues and cancer tissues. The values
were normalized to the average value of normal tissues. (C) Expression levels of HER2 and HER3 in ovarian cancer cell lines SKOV3, A2780, OVCAR-3,
and immortalized ovarian epithelial cell lines IOSE397, IOSE396 were analyzed by immunoblotting.
doi:10.1371/journal.pone.0056647.g003
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Figure 4. Overexpression of HER2 and HER3 reverses miR-199a- and miR-125b-inhibited tumor angiogenesis. (A) Immunoblotting to
confirm establishment of an A2780 cell line stably overexpressing HRE2 and OVCAR-3 cell line stably overexpressing HER3 using pBABEpuro and
pReceiver-Lv105 vector, respectively. (B) Tube formation assay using HUVEC cells was described as in Figure 2. (C) Total tube lengths for each
treatment were analyzed and presented as mean 6 SE (millimeter) from six replicates for each treatment. *Significantly different vs vector+miR-
control (P,0.05). (D, E) A2780 and OVCAR cells were transfected pre-miR-control, pre-miR-199a or pre-miR-125b, respectively; and implanted onto
the CAMs to perform angiogenesis assay as in Figure 2. The representative images from each group were shown here. The total number of blood
vessels in each group was quantified. *,**Significantly different compared with that of the same cell line transfected with pre-miR-control with
*P,0.05 and **P,0.01.
doi:10.1371/journal.pone.0056647.g004
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miR-199a, miR-140, miR-145 and miR-125b were down-regu-
lated in ovarian tumor tissues [22]. Another report showed high
expression of miR-200, miR-141, miR-18a, miR-93, miR-429 and
low expression of let-7b and miR-199a were associated with poor
prognosis in serous ovarian carcinoma [10]. In this study, we
utilized human ovarian epithelial cancer tissues and ovarian
cancer cell lines A2780 and OVCAR-3 to analyze miR-199a and
miR-125b expression levels, and showed that both of them are
down-regulated in ovarian cancer tissues and cells. The functional
analysis revealed that ectopic expression of miR-199a or miR-
125b suppresses tumor angiogenesis both in vitro and in vivo,
indicating that these two miRNAs have anti-angiogenic properties.
VEGF is a key proangiogenic activator which can be activated
at transcriptional level by HIF-1 [13]. To understand the potential
mechanism of miR-199a/125b inhibiting angiogenesis, we initially
analyzed the effect of miR-199a/125b on HIF-1/VEGF expres-
sion. Overexpression of miR-199a/125b dramatically downregu-
lates HIF-1a protein expression as well as VEGF mRNA levels,
suggesting that miR-199a/125b suppresses tumor angiogenesis by
decreasing the expression of HIF-1a and VEGF.
HER2/3 is known to be involved in regulation of HIF-1 activity
and stability [23]. To identify potential upstream molecules of
HIF-1, we investigated the roles of HER2 and HER3 in miR-
199a/125b inhibitory effect on angiogenesis. HER2 and HER3
are overexpressed in ovarian cancer tissues (Figure 3). Our
unpublished data and other researchers showed that miR-125b
targets HER2 and/or HER3 in the cells [16]. Overexpression of
HER2 or HER3 is sufficient to restore inhibitory effects of miR-
199a and miR-125b on tumor angiogenesis, suggesting that HER2
and HER3 are functional targets of miR-199a and miR-125b in
regulating angiogenesis.
We further explored the pathways that may mediate miR-199a
and miR-125b inhibited HIF-1/VEGF expression. HER2/3
signaling is linked to PI3K/Akt pathways [24]. We demonstrate
that delivery of exogenous miR-199a and miR-125b deactivated
PI3K/Akt pathway. One of Akt downstream effectors is p70S6
kinase, a serine-threonine kinase that regulates protein translation
by directly phosphorylating ribosomal protein S6 [25]. In this
study, overexpression miR-199a or miR-125b was sufficient to
inhibit p70S6K1 activation, suggesting HERs/Akt/p70S6K1/
HIF-1a pathway is involved in transmitting the biological effects of
miR-199a or miR-125b. It was reported that HER2 overexpres-
sion enhanced VEGF mRNA level through two promoter
elements [26]. One is the hypoxia responsive element regulated
by HIF-1, and the other is the core promoter region that is
controlled through two adjacent SP1 binding sites. Here we
demonstrate that miR-199a/125b inhibit VEGF expression levels
through transcriptional activation via HIF-1a expression. It was
reported that HIF-1a was targeted by miR-199a in myocytes [14].
But we found that miR-199a inhibited HIF-1a protein expression
through HER2 and HER3 instead of directly targeting HIF-1a in
ovarian cancer cells (Figure S1). Our current study demonstrates
that ectopic expression of miR-199a or miR-125b is sufficient to
inhibit tumor angiogenesis; identifies the functional targets and
pathways involved in miR-199a- and miR-125b-inhibited tumor
angiogenesis; and provides a rationale for new therapeutic
approach to suppress tumor-associated angiogenesis using miR-
199a or miR-125b mimics for ovarian cancer treatment in the
future.
Supporting Information
Figure S1 HIF-1a is not the direct target of miR-199a in
ovarian cancer cells. Luciferase reporter constructs containing
HIF-1a wild-type and mutant 39UTR regions were constructed as
described in Material and Methods. Each luciferase construct was
co-transfected with miRNA precursors and b-gal plasmid into the
cells. The luciferase activities were presented as relative luciferase
activity normalized to those of HIF-1a wild-type 39UTR reporter
and negative control miRNA precursor (pre-miR-control). The
results are obtained from triplicate experiments and presented as
mean 6 SE.
(TIF)
Figure S2 miR-199a inhibits tube formation in cells by
overexpressing HER2 cDNA with 39 UTR region con-
taining miR-199a binding site. A) OVCAR-3 cells were
infected with lentivirus carrying HER2 cDNA with 39 UTR
region, then transiently cotransfected with miR-control or miR-
199a precursor as indicated. HER2 protein levels were determined
72 h after transfection by immunoblotting. B) HUVEC cells were
cultured in serum free medium overnight and re-suspended in
basic EBM-2 medium. The conditioned medium was prepared
from OVCAR-3 cells as treated above. Tube formation assay was
performed as described in Material and Methods. Upper:
Representative images were shown. Scale bar: 200 mm. Lower:
Total tube lengths (mm) were presented as mean 6 SE from six
replicates for each treatment. *Significantly different compared
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Figure 5. Overexpression of HER2 or HER3 in ovarian cancer cells reversed miR-199a and miR-125b inhibitory effects on Akt/
p70S6K1/HIF-1a/VEGF pathway. (A, B) A2780 vector, A2780 HER2, OVCAR-3 vector and OVCAR-3 HER3 cells were cultured under normoxic
condition, and were transfected with pre-miR control, pre-miR-199a and pre-miR-125b precursor at the final concentration of 30 nM. The cells were
harvested and analyzed 70 h after transfection for protein levels of p-Akt, total Akt, p-p70S6K1, p70S6K1, HIF-1a and HIF-1b. (C) RT-PCR was used to
assess the VEGF mRNA levels in stable cells transfected with miR-control, miR-199a or miR-125b. (D) Cells were seeded in 12-well plates and
transiently co-transfected with human VEGF luciferase reporter, pre-miRNAs and b-galactosidase plasmids. The cells were cultured for 48 h after
transfection and relative luciferase activities were measured as described in Method section. (E) A2780 cells stably overexpressing HIF-1a was
established by infecting A2780 cells with retrovirus carrying HIF-1a. (F) A2780 cells and A2780/HIF-1a cells were transiently transfected with the
indicated miRNAs, and harvested 70 h later to analyze VEGF mRNA levels by RT-PCR as indicated in the figure. (G) A2780 vector control cells and
A2780 HIF-1a cells were transfected with pre-miR-control, pre-miR-199a or pre-miR-125b, respectively; then 26106 cells were used to perform
angiogenesis assay as described in Figure 2. *Significantly different compared with that of the vector cell line transfected with pre-miR-control
(P,0.05).
doi:10.1371/journal.pone.0056647.g005
MiR-199a and miR-125b Inhibit Tumor Angiogenesis
PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e56647
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008.
CA Cancer J Clin 58: 71–96.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007.
CA Cancer J Clin 57: 43–66.
3. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, et al. 2005) Annual
report to the nation on the status of cancer, 1975–2002, featuring population-
based trends in cancer treatment. J Natl Cancer Inst 97: 1407–1427.
4. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med
285: 1182–1186.
5. Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and
therapeutic targets. Nat Med 17: 1359–1370.
6. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S (2007) Role of Dicer and
Drosha for endothelial microRNA expression and angiogenesis. Circ Res 101:
59–68. CIRCRESAHA.107.153916 [pii];10.1161/CIRCRESAHA.107.153916
[doi].
7. Plummer PN, Freeman R, Taft R, Vider J, Sax M, et al. (2012) MicroRNAs
regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer
Res. 0008–5472.CAN-12–0271 [pii];10.1158/0008-5472.CAN-12-0271 [doi].
8. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, et al. (2012)
Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by
activation of VEGF-A in oral cancer. Br J Cancer 107: 700–706. bjc2012330
[pii];10.1038/bjc.2012.330 [doi].
9. Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, et al. (2011)
Role of microRNAs in endothelial cell pathophysiology. Pol Arch Med Wewn
121: 361–366. AOP18 [pii].
10. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) MicroRNA
expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690–
2695.
11. Maines-Bandiera SL, Kruk PA, Auersperg N (1992) Simian virus 40-
transformed human ovarian surface epithelial cells escape normal growth
controls but retain morphogenetic responses to extracellular matrix. Am J Obstet
Gynecol 167: 729–735.
12. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, et al. (2008) MicroRNA
expression profiling in human ovarian cancer: miR-214 induces cell survival and
cisplatin resistance by targeting PTEN. Cancer Res 68: 425–433.
13. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of
vascular endothelial growth factor gene transcription by hypoxia-inducible factor
1. Mol Cell Biol 16: 4604–4613.
14. Rane S, He M, Sayed D, Vashistha H, Malhotra A, et al. (2009) Downregulation
of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and
recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 104: 879–
886.
15. He J, Xu Q, Jing Y, Agani F, Qian X, et al. (2012) Reactive oxygen species
regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA
methylation. EMBO Rep 13: 1116–1122.
16. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, et al. (2007)
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-
RNA miR-125a or miR-125b. J Biol Chem 282: 1479–1486.
17. Engelman JA, Cantley LC (2006) The role of the ErbB family members in non-
small cell lung cancers sensitive to epidermal growth factor receptor kinase
inhibitors. Clin Cancer Res 12: 4372s–4376s.
18. Testa JR, Tsichlis PN (2005) AKT signaling in normal and malignant cells.
Oncogene 24: 7391–7393.
19. Abe Y, Yoon SO, Kubota K, Mendoza MC, Gygi SP, et al. (2009) p90
ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the
eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient
signaling. J Biol Chem 284: 14939–14948.
20. Liu LZ, Zheng JZ, Wang XR, Jiang BH (2008) Endothelial p70 S6 kinase 1 in
regulating tumor angiogenesis. Cancer Res 68: 8183–8188.
21. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, et al. (2006) ErbB2
increases vascular endothelial growth factor protein synthesis via activation of
mammalian target of rapamycin/p70S6K leading to increased angiogenesis and
spontaneous metastasis of human breast cancer cells. Cancer Res 66: 2028–
2037.
22. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA
signatures in human ovarian cancer. Cancer Res 67: 8699–8707.
23. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu)
signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha)
synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth
factor expression. Mol Cell Biol 21: 3995–4004.
24. Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway: a
model for targeted therapy. Clin Cancer Res 12: 5268–5272.
25. Dufner A, Thomas G (1999) Ribosomal S6 kinase signaling and the control of
translation. Exp Cell Res 253: 100–109.
26. Pore N, Liu S, Shu HK, Li B, Haas-Kogan D, et al. (2004) Sp1 is involved in
Akt-mediated induction of VEGF expression through an HIF-1-independent
mechanism. Mol Biol Cell 15: 4841–4853.
MiR-199a and miR-125b Inhibit Tumor Angiogenesis
PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e56647
